LEADER 01008nam0 22002651i 450 
001 UON00404807
005 20231205104713.123
100   $a20120207d1972       |0itac50      ba
101   $aita
102   $aIT
105   $a||||    |||||
200 1 $aˆLa ‰società e le cose$esociologia e ideologia da Durkheim a Goffman$fPaolo Maranini
210   $aMilano$cIstituto Librario Internazionale$dc1972
215   $a192 p.$d19 cm.
606   $aIDEOLOGIA$3UONC026353$2FI
606   $aSociologia$3UONC066918$2FI
620   $aIT$dMilano$3UONL000005
700  1$aMaranini$bPaolo$3UONV207466$0127849
712   $aIstituto Librario Internazionale$3UONV273033$4650
801   $aIT$bSOL$c20250221$gRICA
899   $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI
912   $aUON00404807
950   $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI A                       A           0153                $eSI SC 1551     5        0153                $sBuono
996   $aSocietà e le cose$9162326
997   $aUNIOR

LEADER 03205oam  2200985zu 450 
001 9910703085703321
005 20230902162045.0
010   $a0-585-21143-4
035   $a(CKB)111000211325648
035   $a(SSID)ssj0000238714
035   $a(PQKBManifestationID)12076199
035   $a(PQKBTitleCode)TC0000238714
035   $a(PQKBWorkID)10234073
035   $a(PQKB)10414703
035   $a(OCoLC)746570155
035   $a(OCoLC)746498364
035   $a(EXLCZ)99111000211325648
100   $a20160829d2000      uy 
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aRitalin : theory and practice
210 31$a[Place of publication not identified]$cM A Liebert Publishers$d2000
215   $a1 online resource (2 unnumbered pages) $cillustrations
225 1 $aDatos ra?pidos
225 1 $aPreguntas y respuestas
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-913113-82-4 
410  0$aDatos ra?pidos (National Drug Intelligence Center (U.S.))
410  0$aPreguntas y respuestas (National Drug Intelligence Center (U.S.))
606   $aMethylphenidate$xChemotherapy
606   $aAttention-deficit hyperactivity disorder
606   $aPharmacology
606   $aMethylphenidate
606   $aDrug Therapy
606   $aAttention Deficit Disorder with Hyperactivity
606   $aPiperidines
606   $aBiological Science Disciplines
606   $aAttention Deficit and Disruptive Behavior Disorders
606   $aPhenylacetates
606   $aTherapeutics
606   $aHeterocyclic Compounds, 1-Ring
606   $aNeurodevelopmental Disorders
606   $aAcids, Carbocyclic
606   $aNatural Science Disciplines
606   $aMental Disorders
606   $aCarboxylic Acids
606   $aHeterocyclic Compounds
606   $aOrganic Chemicals
606   $aPediatrics$2HILCC
606   $aMedicine$2HILCC
606   $aHealth & Biological Sciences$2HILCC
615  0$aMethylphenidate$xChemotherapy.
615  0$aAttention-deficit hyperactivity disorder.
615  2$aPharmacology.
615  2$aMethylphenidate.
615  2$aDrug Therapy.
615  2$aAttention Deficit Disorder with Hyperactivity.
615  2$aPiperidines.
615  2$aBiological Science Disciplines.
615  2$aAttention Deficit and Disruptive Behavior Disorders.
615  2$aPhenylacetates.
615  2$aTherapeutics.
615  2$aHeterocyclic Compounds, 1-Ring.
615  2$aNeurodevelopmental Disorders.
615  2$aAcids, Carbocyclic.
615  2$aNatural Science Disciplines.
615  2$aMental Disorders.
615  2$aCarboxylic Acids.
615  2$aHeterocyclic Compounds.
615  2$aOrganic Chemicals.
615  7$aPediatrics
615  7$aMedicine
615  7$aHealth & Biological Sciences
676   $a618.92/8589061
702   $aOsman$b Betty B.
702   $aGreenhill$b Laurence L.
712 02$aNational Drug Intelligence Center (U.S.)
801  0$bPQKB
906   $aBOOK
912   $a9910703085703321
996   $aRitalin : theory and practice$93135036
997   $aUNINA